AB Science granted authorization to initiate Phase II study in patients with severe mast cell activation syndrome by the French Health Authority (ANSM)

19/01/2022 – AB Science today announces that it has been authorized by the French Medicine Agency, ANSM, to initiate a Phase II study (AB20006) in patients with severe mast cell activation syndrome